Jiang-Fan Chen Selected Research

Biomarkers (Surrogate Marker)

1/2016	Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy.
9/2006	Psychosis pathways converge via D2high dopamine receptors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jiang-Fan Chen Research Topics

Disease

34	Parkinson Disease (Parkinson's Disease) 02/2024 - 02/2002
13	Brain Injuries (Brain Injury) 02/2019 - 10/2004
12	Hypoxia (Hypoxemia) 02/2024 - 06/2002
12	Inflammation (Inflammations) 01/2019 - 01/2003
8	Neuroinflammatory Diseases 08/2023 - 01/2008
8	Traumatic Brain Injuries (Traumatic Brain Injury) 08/2023 - 04/2010
8	Cognitive Dysfunction 08/2023 - 11/2013
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 12/2007
8	Huntington Disease (Huntington's Disease) 07/2015 - 05/2007
7	Dyskinesias (Dyskinesia) 03/2013 - 11/2003
6	Pathologic Neovascularization 02/2024 - 12/2010
6	Retinopathy of Prematurity (Retrolental Fibroplasia) 02/2024 - 12/2010
6	Multiple Sclerosis 01/2023 - 12/2007
6	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2023 - 02/2009
6	Schizophrenia (Dementia Praecox) 12/2015 - 09/2006
5	Hyperoxia 02/2024 - 12/2015
5	Alzheimer Disease (Alzheimer's Disease) 08/2023 - 12/2007
5	Wounds and Injuries (Trauma) 02/2019 - 06/2002
5	Stroke (Strokes) 01/2019 - 12/2007
5	Nervous System Diseases (Neurological Disorders) 02/2009 - 12/2005
4	Demyelinating Diseases (Demyelinating Disease) 02/2022 - 02/2009
4	Myopia 11/2021 - 01/2011
4	Brain Ischemia (Cerebral Ischemia) 02/2017 - 10/2009
3	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2024 - 01/2016
3	Mental Disorders (Mental Disorder) 01/2023 - 01/2008
3	Blindness (Hysterical Blindness) 01/2018 - 01/2017
3	Fibrosis (Cirrhosis) 10/2016 - 08/2006
3	Psychotic Disorders (Schizoaffective Disorder) 07/2007 - 06/2003
2	Blast Injuries 02/2019 - 02/2010
2	Sleep Wake Disorders 01/2019 - 01/2019
2	Sepsis (Septicemia) 01/2019 - 10/2006
2	Retinal Neovascularization 01/2018 - 12/2010
2	Synucleinopathies 01/2018 - 01/2016
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 02/2017 - 11/2009
2	Infarction (Infarctions) 02/2017 - 10/2004
2	Neurobehavioral Manifestations 12/2015 - 04/2013
2	Gliosis 07/2015 - 11/2013
2	Arthritis (Polyarthritis) 01/2015 - 01/2003
2	Body Weight (Weight, Body) 10/2012 - 07/2009
2	Hyperemia 05/2009 - 10/2008
2	Neoplasms (Cancer) 08/2006 - 07/2004
2	Ischemia 10/2004 - 09/2003
1	Neurocognitive Disorders (Clerambault Syndrome) 01/2024
1	Disease Progression 01/2023
1	Sudden Unexpected Death in Epilepsy 01/2022

Drug/Important Bio-Agent (IBA)

52	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 02/2024 - 06/2002
36	Adenosine (Adenocard)FDA LinkGeneric 01/2024 - 06/2002
23	Caffeine (No Doz)FDA LinkGeneric 08/2023 - 09/2002
20	Purinergic P1 Receptors (Adenosine Receptor)IBA 10/2019 - 06/2002
9	Levodopa (L Dopa)FDA LinkGeneric 01/2023 - 02/2002
9	Glutamic Acid (Glutamate)FDA Link 12/2015 - 01/2008
8	Dopamine (Intropin)FDA LinkGeneric 12/2015 - 12/2003
7	Oxygen (Dioxygen)IBA 02/2024 - 12/2010
7	Retinaldehyde (Retinal)IBA 02/2024 - 12/2010
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2024 - 06/2002
7	istradefyllineIBA 08/2023 - 07/2015
6	CytokinesIBA 01/2019 - 10/2004
5	Neurotransmitter Agents (Neurotransmitter)IBA 01/2023 - 09/2009
4	SynucleinsIBA 02/2024 - 01/2016
4	Adenosine A2 Receptor AntagonistsIBA 04/2022 - 12/2006
4	CollagenIBA 11/2021 - 01/2013
4	Small Interfering RNA (siRNA)IBA 01/2021 - 08/2006
4	Neuroprotective AgentsIBA 03/2008 - 11/2003
4	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 03/2008 - 09/2002
3	alpha-SynucleinIBA 02/2024 - 01/2022
3	EnzymesIBA 11/2021 - 09/2007
3	Adenosine A1 ReceptorIBA 02/2017 - 12/2015
3	Dopamine Agonists (Dopamine Agonist)IBA 04/2015 - 12/2003
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2011 - 09/2006
3	LigandsIBA 01/2011 - 12/2007
3	Amphetamine (Amfetamine)FDA LinkGeneric 07/2007 - 06/2003
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2024 - 04/2013
2	Proteins (Proteins, Gene)FDA Link 08/2023 - 12/2005
2	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA 01/2022 - 10/2019
2	Kainic Acid (Kainate)IBA 01/2022 - 11/2018
2	Adenosine KinaseIBA 01/2022 - 01/2008
2	AcidsIBA 01/2021 - 01/2003
2	Coffee FDA Link 02/2019 - 03/2013
2	Ethanol (Ethyl Alcohol)IBA 01/2019 - 09/2006
2	Biomarkers (Surrogate Marker)IBA 01/2016 - 09/2006
2	MicroRNAs (MicroRNA)IBA 03/2015 - 02/2014
2	ChromatinIBA 03/2015 - 01/2012
2	histone H3 trimethyl Lys4IBA 03/2015 - 01/2015
2	ZM 241385 (ZM241385)IBA 04/2010 - 08/2006
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010 - 10/2006
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 02/2010 - 12/2005
2	Purinergic P1 Receptor AntagonistsIBA 05/2009 - 08/2006
1	Purinergic Receptors (Receptors, Purine)IBA 01/2023
1	Amyloid (Amyloid Fibrils)IBA 01/2023
1	ElementsIBA 01/2023
1	Protein AggregatesIBA 01/2023
1	Equilibrative Nucleoside Transporter 1IBA 11/2022
1	Natalizumab (Tysabri)FDA Link 02/2022

Therapy/Procedure

10	Therapeutics 02/2024 - 01/2003
3	Punctures 01/2019 - 10/2006
3	Drug Therapy (Chemotherapy) 09/2009 - 12/2007
2	Ligation 01/2019 - 10/2006
2	Lasers (Laser) 01/2018 - 10/2008
2	Electroacupuncture 02/2017 - 01/2015
1	Brain-Computer Interfaces 01/2024